In:
CNS & Neurological Disorders - Drug Targets, Bentham Science Publishers Ltd., Vol. 23, No. 2 ( 2024-02), p. 203-214
Abstract:
Bell palsy is a non-progressive neurological condition characterized by the acute onset of
ipsilateral seventh cranial nerve paralysis. People who suffer from this type of facial paralysis develop a droop on one side of their face, or sometimes both. This condition is distinguished by a sudden onset
of facial paralysis accompanied by clinical features such as mild fever, postauricular pain, dysgeusia, hyperacusis, facial changes, and drooling or dry eyes. Epidemiological evidence suggests that 15 to 23
people per 100,000 are affected each year, with a recurrence rate of 12%. It could be caused by ischaemic compression of the seventh cranial nerve, which could be caused by viral inflammation.
Pregnant women, people with diabetes, and people with respiratory infections are more likely to have facial paralysis than the general population. Immune, viral, and ischemic pathways are all thought to
play a role in the development of Bell paralysis, but the exact cause is unknown. However, there is evidence that Bell's hereditary proclivity to cause paralysis is a public health issue that has a greater impact
on patients and their families. Delay or untreated Bell paralysis may contribute to an increased risk of facial impairment, as well as a negative impact on the patient's quality of life. For management,
antiviral agents such as acyclovir and valacyclovir, and steroid treatment are recommended. Thus, early diagnosis accompanied by treatment of the uncertain etiology of the disorder is crucial. This paper
reviews mechanistic approaches, and emerging medical perspectives on recent developments that encounter Bell palsy disorder.
Type of Medium:
Online Resource
ISSN:
1871-5273
DOI:
10.2174/1871527322666230321120618
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2024
SSG:
15,3
Permalink
